MetaCap

AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.69-0.78 (-7.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ABCL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.48
52-week range
2.75 – 15.02
Day range
9.58 – 10.26
Volume / Avg
4.24M / 4.34M
Beta
—

52-week range

$2.75$15.02

ABCL stock today

Shares of AbCellera Biologics (ABCL) finished lower on Nov 20 at $9.69, a drop of 7.45% or $0.78 per share, versus the S&P 500's 3.70% decline. At this level, ABCL sits in the middle of its 52-week range of $2.75 to $15.02: 35.5% below the high, set on Sep 30, 2026 and 253.0% above the low. ABCL is up 183.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 176.1%.

AbCellera Biologics has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About AbCellera Biologics

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Carl L.G. Hansen Ph.D.
Headquarters
Vancouver, BC
Employees
562
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, AbCellera Biologics generated $75.1 million in revenue, up 160.6% from fiscal 2024. AbCellera Biologics reported a net loss of $146.4 million, compared with a loss of $162.9 million a year earlier. Operating margin was -289.0%.

AbCellera Biologics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$75.13M$28.83M$38.02M$485.42M$375.20M
Growth+160.56%-24.17%-92.17%+29.38%+60.92%
Net income$-146.41M$-162.86M$-146.40M$158.52M$153.46M
EPS (diluted)$-0.49$-0.55$-0.51$0.50$0.48

Analyst forecast

Forecast

Consensus (13 analysts)

strong_buy

Avg. price target

$18.67+92.67%

  • Strong buy 2
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $14.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.13 vs $-0.18
Surprise
+27.78%

ABCL news

All ABCL news

AbCellera Biologics peers

Health Care sector
ABCL peer companies
CompanyPrice% ChgMarket capCompare
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs ABCL
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs ABCL
BHCBausch Health Companies Inc.8.22-3.97%$3.08Bvs ABCL
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs ABCL
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs ABCL
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs ABCL
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs ABCL
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs ABCL

Indexes, lists and sector

AbCellera Biologics stock FAQ

What is AbCellera Biologics's stock price today?

ABCL last traded at $9.69 as of Nov 20, 4:00 PM EST, down 7.45% on the day. Prices are delayed at least 15 minutes.

Who is AbCellera Biologics's CEO?

Dr. Carl L.G. Hansen Ph.D. is the chief executive officer of AbCellera Biologics Inc., which has about 562 employees.

What is the ABCL 52-week high?

The 52-week high for ABCL is $15.02 and the 52-week low is $2.75. The stock is currently 35.5% below its high.

Compare ABCL